At the end of the study , a higher reduction in metabolic syndrome prevalence was observed in group 1 ( -38.1 % ) compared with group 2 ( -12.7 % ; relative risk , 0.237 ; 95 % CI , 0.092-0 .608 ; P = 0.003 ) .